Clinical and Biomarker Profiles and Prognosis of Elderly Patients With Coronavirus Disease 2019 (COVID-19) With Cardiovascular Diseases and/or Risk Factors.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
25 05 2021
Historique:
pubmed: 7 5 2021
medline: 3 6 2021
entrez: 6 5 2021
Statut: ppublish

Résumé

This study investigated the effects of age on the outcomes of coronavirus disease 2019 (COVID-19) and on cardiac biomarker profiles, especially in patients with cardiovascular diseases and/or risk factors (CVDRF).Methods and Results:A nationwide multicenter retrospective study included 1,518 patients with COVID-19. Of these patients, 693 with underlying CVDRF were analyzed; patients were divided into age groups (<55, 55-64, 65-79, and ≥80 years) and in-hospital mortality and age-specific clinical and cardiac biomarker profiles on admission evaluated. Overall, the mean age of patients was 68 years, 449 (64.8%) were male, and 693 (45.7%) had underlying CVDRF. Elderly (≥80 years) patients had a significantly higher risk of in-hospital mortality regardless of concomitant CVDRF than younger patients (P<0.001). Typical characteristics related to COVID-19, including symptoms and abnormal findings on baseline chest X-ray and computed tomography scans, were significantly less prevalent in the elderly group than in the younger groups. However, a significantly (P<0.001) higher proportion of elderly patients were positive for cardiac troponin (cTn), and B-type natriuretic peptide (BNP) and N-terminal pro BNP (NT-proBNP) levels on admission were significantly higher among elderly than younger patients (P<0.001 and P=0.001, respectively). Elderly patients with COVID-19 had a higher risk of mortality during the hospital course, regardless of their history of CVDRF, were more likely to be cTn positive, and had significantly higher BNP/NT-proBNP levels than younger patients.

Sections du résumé

BACKGROUND
This study investigated the effects of age on the outcomes of coronavirus disease 2019 (COVID-19) and on cardiac biomarker profiles, especially in patients with cardiovascular diseases and/or risk factors (CVDRF).Methods and Results:A nationwide multicenter retrospective study included 1,518 patients with COVID-19. Of these patients, 693 with underlying CVDRF were analyzed; patients were divided into age groups (<55, 55-64, 65-79, and ≥80 years) and in-hospital mortality and age-specific clinical and cardiac biomarker profiles on admission evaluated. Overall, the mean age of patients was 68 years, 449 (64.8%) were male, and 693 (45.7%) had underlying CVDRF. Elderly (≥80 years) patients had a significantly higher risk of in-hospital mortality regardless of concomitant CVDRF than younger patients (P<0.001). Typical characteristics related to COVID-19, including symptoms and abnormal findings on baseline chest X-ray and computed tomography scans, were significantly less prevalent in the elderly group than in the younger groups. However, a significantly (P<0.001) higher proportion of elderly patients were positive for cardiac troponin (cTn), and B-type natriuretic peptide (BNP) and N-terminal pro BNP (NT-proBNP) levels on admission were significantly higher among elderly than younger patients (P<0.001 and P=0.001, respectively).
CONCLUSIONS
Elderly patients with COVID-19 had a higher risk of mortality during the hospital course, regardless of their history of CVDRF, were more likely to be cTn positive, and had significantly higher BNP/NT-proBNP levels than younger patients.

Identifiants

pubmed: 33952834
doi: 10.1253/circj.CJ-21-0160
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Troponin 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

921-928

Auteurs

Shingo Matsumoto (S)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine.

Shunsuke Kuroda (S)

Department of Cardiology, Kameda Medical Center.
Department of Cardiovascular Medicine, Cleveland Clinic.

Takahide Sano (T)

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine.
Department of Cardiology, Ebara Hospital.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, Kobe City Medical Center General Hospita.

Taishi Yonetsu (T)

Department of Cardiovascular Medicine, Tokyo Medical and Dental University.

Shun Kohsaka (S)

Department of Cardiology, Keio University School of Medicine.

Sho Torii (S)

Department of Cardiology, Tokai University School of Medicine.

Takuya Kishi (T)

Department of Graduate School of Medicine (Cardiology), International University of Health and Welfare.

Issei Komuro (I)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.

Ken-Ichi Hirata (KI)

Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.

Koichi Node (K)

Department of Cardiovascular Medicine, Saga University.

Yuya Matsue (Y)

Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine.
Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH